SPEN
protein-codingspen family transcriptional repressor, the group of RNA binding motif containing
Gene summary
This gene encodes a hormone inducible transcriptional repressor. Repression of transcription by this gene product can occur through interactions with other repressors, by the recruitment of proteins involved in histone deacetylation, or through sequestration of transcriptional activators. The product of this gene contains a carboxy-terminal domain that permits binding to other corepressor proteins. This domain also permits interaction with members of the NuRD complex, a nucleosome remodeling protein complex that contains deacetylase activity. In addition, this repressor contains several RNA recognition motifs that confer binding to a steroid receptor RNA coactivator; this binding can modulate the activity of both liganded and nonliganded steroid receptors. [provided by RefSeq, Jul 2008]
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~104.4 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: AD
Disease ID:MONDO:0859143
Submitter: ClinGen
The SPEN gene is located on chromosome 1 at 1p36.21-p36.13 and appears to function as a nuclear matrix platform that organizes and integrates transcriptional responses, and is thought to be involved in chromatin remodeling. SPEN was first reported in relation to autosomal dominant SPEN-related neurodevelopmental disorder in 2021 by Radio et al. (PMID: 33596411). The clinical profile of this disease includes developmental delay/intellectual disability, autism spectrum disorder, behavioral abnormalities, hypotonia, brain and spine anomalies, congenital heart defects, gait imbalance, variable facial dysmorphisms, and obesity/increased BMI, especially in females. This curation included 7 unique truncating variants (4 nonsense and 3 frameshift) in 7 probands from 1 publication (PMID: 33596411). The majority of cases showed de novo inheritance, but familial inheritance in one family was scored. Note there are additional unpublished cases. The maximum score for genetic evidence (12 pts.) has been reached. The mechanism of pathogenicity appears to be loss of function. This gene-disease relationship is also supported by experimental evidence including expression in the developing human neocortex and several animal models (Drosophila and conditional knockout mouse) in which inactivation of SPEN was associated with a neuronal phenotype (PMIDs: 10704397, 17457934). In summary, there is definitive evidence supporting the relationship between SPEN and autosomal dominant SPEN-related neurodevelopmental disorder. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time. This classification was approved by the ClinGen Syndromic Disorders Gene Curation Expert Panel on the meeting date 11/01/2023.
Inheritance Pattern: AD
Disease ID:MONDO:0859143
Submitter: PanelApp Australia
Inheritance Pattern: AD
Disease ID:MONDO:0859143
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: AD
Disease ID:MONDO:0100038
Submitter: Illumina
Inheritance Pattern: AD
Disease ID:MONDO:0859143
Submitter: G2P
Clinical Genomic Database (CGD)
Manifestation: Cardiovascular; Craniofacial; Endocrine; Musculoskeletal; Neurologic
Intervention: Cardiovascular
Rationale: The condition can involve congenital cardiac anomalies, and awareness may allow early management
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to SPEN variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_015001.3. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 6 | 126 | 6 | 138 | ||
| missense | 1 | 629 | 133 | 16 | 779 | |
| nonsense | 24 | 22 | 6 | 52 | ||
| start loss | 0 | |||||
| frameshift | 41 | 30 | 3 | 74 | ||
| splice donor/acceptor (+/-2bp) | 1 | 6 | 7 | |||
| Total | 67 | 52 | 650 | 259 | 22 | 1050 |
Highest pathogenic variant AF is 0.0000065733257
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_055816.2 | 15 | MANE Select | |
| Ensembl | ENSP00000364912.3 | 15 | MANE Select | |
| Ensembl | ENSP00000388021.2 | 2 | Standard | |
| Ensembl | ENSP00000400914.1 | 7 | Standard |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Pathways ConsensusPathDB
- Notch Signaling Pathway
- Notch
- Notch
- Notch signaling pathway
- Notch-mediated HES/HEY network
Biological Process
- negative regulation of transcription by RNA polymerase II
- Notch signaling pathway
- viral process
- negative regulation of transcription, DNA-templated
- positive regulation of neurogenesis
Molecular Function
- RNA polymerase II transcription factor binding
- DNA binding
- transcription corepressor activity
- RNA binding
- protein binding
Cellular Component
- nucleus
- nucleoplasm
- transcriptional repressor complex
- extracellular exosome
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000375759
- Coding exons
- 15
- Length
- 92597
- Individuals with no LoFs
- 125730
- Homozygous LoFs
- 0
- Heterozygous LoFs
- 18
- Defined
- 125748
- p
- 0.0000716
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | 2.89 | 1697 | 2.07e+3 | 0.821 | 0.000124 | 23759 |
| Missense (PolyPhen) | 659 | 975.57 | 0.6755 | 11054 | ||
| Synonymous | -0.323 | 822 | 810 | 1.01 | 0.0000501 | 7710 |
| Loss of Function | 10.2 | 4 | 129 | 0.0310 | 0.00000872 | 1443 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0.000062 | 0.000062 | rare |
| Latino/Admixed American | 0.000058 | 0.000058 | rare |
| Ashkenazi Jewish | 0.000099 | 0.000099 | rare |
| East Asian | 0.000054 | 0.000054 | rare |
| Finnish | 0.00019 | 0.00018 | rare |
| European (Non-Finnish) | 0.000088 | 0.000079 | rare |
| South Asian | 0 | 0.0 | absent |
| Other | 0 | 0.0 | absent |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: May serve as a nuclear matrix platform that organizes and integrates transcriptional responses. In osteoblasts, supports transcription activation: synergizes with RUNX2 to enhance FGFR2- mediated activation of the osteocalcin FGF-responsive element (OCFRE) (By similarity). Has also been shown to be an essential corepressor protein, which probably regulates different key pathways such as the Notch pathway. Negative regulator of the Notch pathway via its interaction with RBPSUH, which prevents the association between NOTCH1 and RBPSUH, and therefore suppresses the transactivation activity of Notch signaling. Blocks the differentiation of precursor B-cells into marginal zone B-cells. Probably represses transcription via the recruitment of large complexes containing histone deacetylase proteins. May bind both to DNA and RNA. {ECO:0000250, ECO:0000269|PubMed:11331609, ECO:0000269|PubMed:12374742}.;
Recessive Scores
- pRec
- 0.160
Intolerance Scores
- LoFtool
- 0.206
- RVIS EVS
- -2.31
- RVIS percentile EVS
- 1.21
Essentials
- Essential (CRISPR)
- E
- Essential (CRISPR2)
- N
- Essential (gene trap)
- K
- Indispensability pred.
- E
- Indispensability score
- 0.859
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |